Company intelligence / Profile preview

AventaMed

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

AventaMed developed the Solo+ Tympanostomy Tube Device (TTD), a single-use instrument that enables rapid, office-based insertion of grommets/ear tubes into the eardrum using only topical anesthesia. This innovation eliminates the need for general anesthesia and operating room time for most pediatric patients. Clinical studies have shown safe and effective use in office settings without escalation to surgery. The technology was acquired by Karl Storz in February 2023.

Therapeutic areas: OtherInfectious Diseases
Modalities: DeviceMedical deviceMedical device (specifically for tympanostomy tube placement)
Industry: Surgical Medical Devices

Partnerships

Collaborated with major healthcare companies ahead of US launchjoined NESTcc real-world evidence test-case consortium

Beyond the preview

Go deeper on AventaMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AventaMed.

Explore the full profile